Literature DB >> 22499341

Genomic analysis of mitochondrial diseases in a consanguineous population reveals novel candidate disease genes.

Hanan E Shamseldin1, Muneera Alshammari, Tarfa Al-Sheddi, Mustafa A Salih, Hisham Alkhalidi, Amal Kentab, Gabriela M Repetto, Mais Hashem, Fowzan S Alkuraya.   

Abstract

OBJECTIVE: To investigate the utility of autozygome analysis and exome sequencing in a cohort of patients with suspected or confirmed mitochondrial encephalomyopathy.
METHODS: Autozygome was used to highlight candidate genes for direct sequencing in 10 probands, all born to consanguineous parents. Autozygome was also used to filter the variants from exome sequencing of four probands.
RESULTS: In addition to revealing mutations in known mitochondrial genes, the analysis revealed the identification of two novel candidate disease genes: MFF and FARS2, encoding the mitochondrial fission factor and phenylalanyl-tRNA synthetase, respectively.
INTERPRETATION: These findings expand the repertoire of genes that are mutated in patients with mitochondrial disorders and highlight the value of integrating genomic approaches in the evaluation of these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22499341     DOI: 10.1136/jmedgenet-2012-100836

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  71 in total

Review 1.  The clinical maze of mitochondrial neurology.

Authors:  Salvatore DiMauro; Eric A Schon; Valerio Carelli; Michio Hirano
Journal:  Nat Rev Neurol       Date:  2013-07-09       Impact factor: 42.937

Review 2.  Mitochondrial dynamics and their potential as a therapeutic target.

Authors:  B N Whitley; E A Engelhart; S Hoppins
Journal:  Mitochondrion       Date:  2019-06-19       Impact factor: 4.160

3.  Mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase, lead to premature ovarian failure and hearing loss in Perrault syndrome.

Authors:  Sarah B Pierce; Ksenija Gersak; Rachel Michaelson-Cohen; Tom Walsh; Ming K Lee; Daniel Malach; Rachel E Klevit; Mary-Claire King; Ephrat Levy-Lahad
Journal:  Am J Hum Genet       Date:  2013-03-28       Impact factor: 11.025

Review 4.  Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease.

Authors:  Stefanie Gerstberger; Markus Hafner; Manuel Ascano; Thomas Tuschl
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 5.  Discovery of mutations for Mendelian disorders.

Authors:  Fowzan S Alkuraya
Journal:  Hum Genet       Date:  2016-04-11       Impact factor: 4.132

Review 6.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

7.  Fluorescent tools to analyse peroxisome-ER interactions in mammalian cells.

Authors:  Alexa Bishop; Maki Kamoshita; Josiah B Passmore; Christian Hacker; Tina A Schrader; Hans R Waterham; Joseph L Costello; Michael Schrader
Journal:  Contact (Thousand Oaks)       Date:  2019-05-15

Review 8.  Human aminoacyl-tRNA synthetases in diseases of the nervous system.

Authors:  Jana Ognjenović; Miljan Simonović
Journal:  RNA Biol       Date:  2017-06-30       Impact factor: 4.652

9.  Compound heterozygosity for loss-of-function FARSB variants in a patient with classic features of recessive aminoacyl-tRNA synthetase-related disease.

Authors:  Anthony Antonellis; Stephanie N Oprescu; Laurie B Griffin; Amer Heider; Andrea Amalfitano; Jeffrey W Innis
Journal:  Hum Mutat       Date:  2018-04-10       Impact factor: 4.878

10.  Novel Compound Heterozygous Mutations Expand the Recognized Phenotypes of FARS2-Linked Disease.

Authors:  Melissa A Walker; Kyle P Mohler; Kyle W Hopkins; Derek H Oakley; David A Sweetser; Michael Ibba; Matthew P Frosch; Ronald L Thibert
Journal:  J Child Neurol       Date:  2016-04-19       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.